The COURAGE trial showed no substantial difference in cardiovascular outcomes among patients who received either optimal medical therapy or optimal therapy plus a percutaneous intervention. Dr. William Weintraub, professor of medicine at Chrisitana Care Health System in Newark, Delaware, describes his cost-benefit analysis of this trial and how cost effectiveness should be measured and evaluated in this patient population. Hosted by Dr. Matthew Sorrentino.
